卵巢癌化疗相关的耐药标志物分析

Analysis of drug resistance-related markers in ovarian cancer

目的:研究肿瘤蛋白P53、凋亡抑制蛋白livin、GST-π以及DNA TopoII在卵巢癌患者中的表达情况,分析其临床意义。方法:本研究选取80例卵巢癌患者,将部分癌变组织作为研究对象,根据复发情况分为化疗敏感组和化疗耐药组。采用免疫组化的方法对基因表达情况进行分析,阐明和临床病理特征的关系。结果:化疗敏感组P53、livin以及GST-π阳性表达量较化疗耐药组明显降低(P<0.01),TopoII阳性表达率显著高于化疗耐药组(P<0.05);5年累积生存率比化疗耐药组显著降低(P<0.05)。结论:P53、livin、GST-π和TopoII可以作为卵巢癌化疗效果和预后评估的指标。

Objective:To study the expression of tumor protein P53,apoptosis inhibitory protein livin,GST-πand DNA TopoII in patients with ovarian cancer,and to analyze its clinical significance.Methods:Eighty patients with ovarian cancer were enrolled in this study.Some cancerous tissues were selected as subjects,and were classified into chemotherapy sensitivity and chemotherapy tolerance according to recurrence.Immunohistochemistry was used to analyze the expression of the above genes,and to clarify the relationship between them and clinical case characteristics.Results:The positive expressions of P53,livin and GST-πin chemotherapy-sensitive group were significantly lower than those in chemotherapy-resistant group(P<0.01),and the positive expression rate of TopoII was significantly higher than that in chemotherapy-resistant group(P<0.05).The chemotherapy-resistant group was significantly lower(P<0.05).Conclusion:P53,livin,GST-πand TopoII can be used as indicators for the evaluation of ovarian cancer chemotherapy and prognosis.